Comparison of adequate relief with symptom, global, and responder endpoints in linaclotide phase 3 trials in IBS‐C
Michael Camilleri(CSIRO Manufacturing), Jeffrey M. Johnston(Ironwood Pharmaceuticals (United States)), Anthony Lembo(Cleveland Clinic), Robyn T. Carson(Forest Research Institute), Valerie Williams(RTI International), Steven J. Shiff(Forest Research Institute), Bernard J. Lavins(Ironwood Pharmaceuticals (United States)), Lauren Nelson(RTI Health Solutions), Caroline B. Kurtz(Ironwood Pharmaceuticals (United States)), Mark G. Currie(Flinders University), James E. MacDougall(BioBridges (United States))
Cited by 17
Related Papers
Bowel Disorders
|Gastroenterology|2016|2.8k
Functional Gastroduodenal Disorders
|Gastroenterology|2006|2.4k
Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
|BMJ|2008|1.2k
Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
|PLoS ONE|2010|910
Intestinal barrier function in health and gastrointestinal disease
|Neurogastroenterology & Motility|2012|886